Yahoo

Eyedrop breakthrough could replace painful eye injections for retinal diseases

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Mor Institute launches initiative to ensure treatment continuity and prevent blindness

Age-related macular degeneration (AMD) is the leading cause of blindness in the West. Delays in injections can cause ...
The American Journal of Managed Care

Visual Acuity, Retinal Sensitivity Improved With Intravitreal Ranibizumab Injection

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...
Nasdaq

Clearside Biomedical Showcases Suprachoroidal Injection Platform for Retinal Diseases at CTS Meeting

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...
WNEM

Breakthroughs For Dry Macular Degeneration Are on the Way

There are two types of macular degeneration: dry and wet. Dry age-related macular degeneration is the most common type — it happens when small deposits form under the retina, causing cells in the ...
Healio

Patients with geographic atrophy require careful screening, opportunity for treatment

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...
Seeking Alpha

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
Nasdaq

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
Fierce Biotech

BCI retinal implant medtech Science closes major $230M series C round

Science has added a whole lot more cash to the bank, bringing in an impressive $230 million in its latest raise. | Science has added a whole lot more cash to the bank, bringing in an impressive $230 ...
Benzinga.com

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
Healio

Specialists navigate changing, challenging landscape of geographic atrophy management

The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and ...